These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

998 related items for PubMed ID: 34176194

  • 1. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV, Nagaraju SP, Bhojaraja MV, Prabhu RA, Rangaswamy D, Rao IR.
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [Abstract] [Full Text] [Related]

  • 2. Slowing Progression in CKD: DAPA CKD and Beyond.
    Larmour K, Levin A.
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1117-1119. PubMed ID: 33692116
    [No Abstract] [Full Text] [Related]

  • 3. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
    Bell DSH, Jerkins T.
    Diabetes Obes Metab; 2024 Jun; 26(6):2046-2053. PubMed ID: 38516874
    [Abstract] [Full Text] [Related]

  • 4. Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.
    Bayne S, LeFevre J, Olstinske K, Ravindran S, Munusamy S.
    Adv Biol (Weinh); 2024 Mar; 8(3):e2300496. PubMed ID: 38065929
    [Abstract] [Full Text] [Related]

  • 5. Transforming the Care of Patients with Diabetic Kidney Disease.
    Brosius FC, Cherney D, Gee PO, Harris RC, Kliger AS, Tuttle KR, Quaggin SE, DKD-Collaborative ASN Taskforce.
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
    [Abstract] [Full Text] [Related]

  • 6. [Renoprotective treatments : renin-angiotensin-aldosterone system blockade and beyond].
    Esnault V.
    Rev Prat; 2024 Jun; 74(6):s19-s22. PubMed ID: 39011717
    [Abstract] [Full Text] [Related]

  • 7. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
    Fletcher RA, Jongs N, Chertow GM, McMurray JJV, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Rockenschaub P, Rossing P, Correa-Rotter R, Toto RD, Vaduganathan M, Wheeler DC, Heerspink HJL, Neuen BL.
    J Am Soc Nephrol; 2023 Dec 01; 34(12):1965-1975. PubMed ID: 37876229
    [Abstract] [Full Text] [Related]

  • 8. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S, Zhao L, Mi Y, He W.
    Diabetes Obes Metab; 2022 Nov 01; 24(11):2159-2168. PubMed ID: 35712807
    [Abstract] [Full Text] [Related]

  • 9. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
    Mima A.
    Adv Ther; 2022 Aug 01; 39(8):3488-3500. PubMed ID: 35751762
    [Abstract] [Full Text] [Related]

  • 10. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
    Vart P, Vaduganathan M, Jongs N, Remuzzi G, Wheeler DC, Hou FF, McCausland F, Chertow GM, Heerspink HJL.
    Clin J Am Soc Nephrol; 2022 Dec 01; 17(12):1754-1762. PubMed ID: 36414316
    [Abstract] [Full Text] [Related]

  • 11. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA, Gariani K, Martin PY.
    Eur J Intern Med; 2014 Feb 01; 25(2):173-6. PubMed ID: 24315413
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E, White WB, Bakris G.
    Postgrad Med; 2023 Apr 01; 135(3):224-233. PubMed ID: 35392754
    [Abstract] [Full Text] [Related]

  • 13. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
    Al Dhaybi O, Bakris GL.
    Diabetes Obes Metab; 2020 Apr 01; 22 Suppl 1():69-76. PubMed ID: 32267074
    [Abstract] [Full Text] [Related]

  • 14. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S, López-Mesa M, Gómez-Fernández P.
    Nefrologia (Engl Ed); 2021 Apr 01; 41(3):258-275. PubMed ID: 36166243
    [Abstract] [Full Text] [Related]

  • 15. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ.
    Curr Diab Rep; 2019 Jan 23; 19(1):4. PubMed ID: 30673886
    [Abstract] [Full Text] [Related]

  • 16. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H, Zhou B, Xu G.
    Cardiovasc Diabetol; 2017 May 16; 16(1):65. PubMed ID: 28511711
    [Abstract] [Full Text] [Related]

  • 17. Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study.
    Martínez-Milla J, García MC, Urquía MT, Castillo ML, Arbiol AD, Monteagudo ALR, Mariscal MLM, Figuero SB, Franco-Pelaéz JA, Tuñón J.
    Drugs Aging; 2019 Dec 16; 36(12):1123-1131. PubMed ID: 31493202
    [Abstract] [Full Text] [Related]

  • 18. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
    Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F.
    Nat Rev Nephrol; 2022 Jan 16; 18(1):56-70. PubMed ID: 34675379
    [Abstract] [Full Text] [Related]

  • 19. Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
    Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI.
    Kidney Int; 2019 Aug 16; 96(2):489-504. PubMed ID: 31142441
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved.
    Sarafidis P, Papadopoulos CE, Kamperidis V, Giannakoulas G, Doumas M.
    Hypertension; 2021 May 05; 77(5):1442-1455. PubMed ID: 33775130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.